Adaptive Biotechnologies Corporation and Takeda entered into a translational collaboration, utilizing Adaptive’s clonoSEQ Assay to assess minimal residual disease, to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies.
Over the years, I have gained extensive experience with academic cancer center External Advisory Boards, including hosting multiple EAB meetings at my own cancer center, chairing the EABs of nine other NCI designated cancer centers, and serving on many others.
